德康医疗

Dexcom's 15min chart triggers Bollinger Bands Narrowing, KDJ Death Cross signal.

Dexcom

Dexcom Eyes International CGM Markets for 2026 Growth

Dexcom: Barclays Downgrades to Underweight with PT at $71 from $80.

DexCom Provides Preliminary Earnings Guidance for Q4 and Full Year 2025, and 2026

Alnylam Pharmaceuticals

Nasdaq 100 Leaders: DexCom Surges 3.6%, Alnylam Pharmaceuticals Drops 8.1%

Catalyst<ul> <li>Small and Extra-large investor inflows show positive fund flow trends, suggesting increasing institutional confidence in DXCM.</li></ul>Risk<ul> <li>Technical indicators show a weak market state with five recent bearish signals, suggesting increased risk of further decline.</li> <li>Analyst ratings show inconsistency, with only one active analyst recommending Buy, indicating uncertainty in institutional outlook.</li></ul>

Key Factors

Barclays downgrades DexCom to Underweight with a price target of $71, a reduction from the previous $80 target. DexCom reports Q4 2025 revenue of $1.26 billion, a 13% increase year-over-year, driven by 11% growth in U.S. revenue and 18% growth in international revenue. Bernstein raises DexCom's price target to $86.00 from $84.00, maintaining an "Outperform" rating and citing the company's glucose monitoring systems and integration with insulin pumps. DexCom provides preliminary 2026 revenue guidance of $5.16–$5.25 billion, representing 11–13% growth, with non-GAAP gross profit margin and operating margin estimates of 63–64% and 22–23%, respectively.

Recent Updates

DXCM News